CN102174536B - 用于重组腺病毒的包装细胞 - Google Patents

用于重组腺病毒的包装细胞 Download PDF

Info

Publication number
CN102174536B
CN102174536B CN2011100542020A CN201110054202A CN102174536B CN 102174536 B CN102174536 B CN 102174536B CN 2011100542020 A CN2011100542020 A CN 2011100542020A CN 201110054202 A CN201110054202 A CN 201110054202A CN 102174536 B CN102174536 B CN 102174536B
Authority
CN
China
Prior art keywords
cell
sequence
adenovirus
genome
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2011100542020A
Other languages
English (en)
Chinese (zh)
Other versions
CN102174536A (zh
Inventor
罗纳德·福格尔斯
门佐·扬斯·埃姆科·哈文戈
戴维·A·T·M··祖伊德格斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Vaccines and Prevention BV
Original Assignee
Crucell Holand BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holand BV filed Critical Crucell Holand BV
Publication of CN102174536A publication Critical patent/CN102174536A/zh
Application granted granted Critical
Publication of CN102174536B publication Critical patent/CN102174536B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/38—Vector systems having a special element relevant for transcription being a stuffer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
CN2011100542020A 2003-10-02 2004-10-04 用于重组腺病毒的包装细胞 Expired - Fee Related CN102174536B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP0350679 2003-10-02
EPPCT/EP03/50679 2003-10-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2004800286959A Division CN1863918B (zh) 2003-10-02 2004-10-04 用于重组腺病毒的包装细胞

Publications (2)

Publication Number Publication Date
CN102174536A CN102174536A (zh) 2011-09-07
CN102174536B true CN102174536B (zh) 2013-02-13

Family

ID=34400432

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2004800286959A Expired - Fee Related CN1863918B (zh) 2003-10-02 2004-10-04 用于重组腺病毒的包装细胞
CN2011100542020A Expired - Fee Related CN102174536B (zh) 2003-10-02 2004-10-04 用于重组腺病毒的包装细胞

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN2004800286959A Expired - Fee Related CN1863918B (zh) 2003-10-02 2004-10-04 用于重组腺病毒的包装细胞

Country Status (15)

Country Link
US (2) US7816104B2 (enExample)
EP (1) EP1670925B1 (enExample)
JP (1) JP4749334B2 (enExample)
KR (1) KR101203817B1 (enExample)
CN (2) CN1863918B (enExample)
AU (1) AU2004278517B2 (enExample)
BR (1) BRPI0414670A (enExample)
CA (1) CA2538025C (enExample)
DK (1) DK1670925T3 (enExample)
EA (1) EA010924B1 (enExample)
HR (1) HRP20130616T1 (enExample)
IL (2) IL174489A (enExample)
NZ (1) NZ545501A (enExample)
SI (1) SI1670925T1 (enExample)
WO (1) WO2005033320A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
CN1863918B (zh) 2003-10-02 2011-03-30 克鲁塞尔荷兰公司 用于重组腺病毒的包装细胞
EP1998804B1 (en) * 2006-03-27 2014-04-16 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
US20100263066A1 (en) * 2007-04-30 2010-10-14 Medtronic, Inc Inert dna sequences for efficient viral packaging and methods of use
NZ593235A (en) 2008-11-03 2013-02-22 Crucell Holland Bv Method for the production of recombinant adenovirus serotype 35
EP2784155B1 (en) * 2011-11-24 2018-06-13 Viromed Co. Ltd. Adenovirus producing novel cell line and the use thereof
WO2013079473A1 (en) 2011-11-28 2013-06-06 Crucell Holland B.V. Influenza virus vaccines and uses thereof
AP2014007993A0 (en) * 2012-03-22 2014-10-31 Crucell Holland Bv Vaccine against RSV
WO2018194438A1 (ko) 2017-04-21 2018-10-25 (주)지뉴인텍 비복제 아데노 바이러스 생산 세포주 및 이의 제조방법
CN108342362A (zh) * 2018-01-31 2018-07-31 武汉枢密脑科学技术有限公司 一种用于扩增重组犬腺病毒cav2的稳定细胞系mdck及其构建方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994128A (en) * 1995-06-15 1999-11-30 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
WO2002040665A2 (en) * 2000-11-15 2002-05-23 Crucell Holland B.V. Complementing cell lines
WO2003031633A2 (de) * 2001-10-04 2003-04-17 Probiogen Ag Adenovirales vektorsystem

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889806A (en) * 1987-04-15 1989-12-26 Washington University Large DNA cloning system based on yeast artificial chromosomes
US5610053A (en) 1993-04-07 1997-03-11 The United States Of America As Represented By The Department Of Health And Human Services DNA sequence which acts as a chromatin insulator element to protect expressed genes from cis-acting regulatory sequences in mammalian cells
US5834256A (en) * 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US5820868A (en) 1993-12-09 1998-10-13 Veterinary Infectious Disease Organization Recombinant protein production in bovine adenovirus expression vector system
WO1995034671A1 (en) 1994-06-10 1995-12-21 Genvec, Inc. Complementary adenoviral vector systems and cell lines
WO1996017053A1 (en) 1994-11-28 1996-06-06 Genetic Therapy, Inc. Vectors for tissue-specific replication
AU709498B2 (en) 1994-12-12 1999-09-02 Genetic Therapy, Inc. Improved adenoviral vectors and producer cells
WO2000063403A2 (en) 1999-04-15 2000-10-26 Crucell Holland B.V. Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein
US6558948B1 (en) 1999-11-23 2003-05-06 Stefan Kochanek Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
ATE466943T1 (de) 2001-07-04 2010-05-15 Chromagenics Bv Dns-sequenzen mit anti-repressor aktivität
US7026164B2 (en) * 2003-07-03 2006-04-11 Cell Genesys, Inc. Adenovirus packaging cell lines
CN1863918B (zh) 2003-10-02 2011-03-30 克鲁塞尔荷兰公司 用于重组腺病毒的包装细胞

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994128A (en) * 1995-06-15 1999-11-30 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
WO2002040665A2 (en) * 2000-11-15 2002-05-23 Crucell Holland B.V. Complementing cell lines
WO2003031633A2 (de) * 2001-10-04 2003-04-17 Probiogen Ag Adenovirales vektorsystem

Also Published As

Publication number Publication date
US8114637B2 (en) 2012-02-14
CN102174536A (zh) 2011-09-07
SI1670925T1 (sl) 2013-10-30
NZ545501A (en) 2010-12-24
EA200600693A1 (ru) 2006-10-27
IL227543A (en) 2015-08-31
HK1084974A1 (en) 2006-08-11
CN1863918B (zh) 2011-03-30
AU2004278517A1 (en) 2005-04-14
EP1670925A1 (en) 2006-06-21
EA010924B1 (ru) 2008-12-30
JP4749334B2 (ja) 2011-08-17
HRP20130616T1 (en) 2013-08-31
JP2007507216A (ja) 2007-03-29
AU2004278517B2 (en) 2010-04-01
IL174489A0 (en) 2006-08-01
WO2005033320A1 (en) 2005-04-14
US20060183232A1 (en) 2006-08-17
IL174489A (en) 2013-10-31
KR20060095557A (ko) 2006-08-31
EP1670925B1 (en) 2013-05-01
CN1863918A (zh) 2006-11-15
KR101203817B1 (ko) 2012-11-23
BRPI0414670A (pt) 2006-11-21
US7816104B2 (en) 2010-10-19
US20100311172A1 (en) 2010-12-09
CA2538025C (en) 2012-07-17
DK1670925T3 (da) 2013-07-08
CA2538025A1 (en) 2005-04-14

Similar Documents

Publication Publication Date Title
US9228205B2 (en) Complementing cell lines
US8114637B2 (en) Packaging cells for recombinant adenovirus
Lusky et al. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted
Dormond et al. From the first to the third generation adenoviral vector: what parameters are governing the production yield?
Southgate et al. Gene transfer into neural cells in vitro using adenoviral vectors
JP2003510089A (ja) 複製能力のあるアデノウイルスのないｅ１欠失アデノウイルスの製造に有用な細胞系及び構築物
CA2590943C (en) Cell lines for production of replication-defective adenovirus
Zou et al. ☆ DNA assembly technique simplifies the construction of infectious clone of fowl adenovirus
CA2461579C (en) Porcine adenovirus e1 region
Ruzsics et al. Transposon-Assisted Cloning and Traceless Mutagenesis of Adenoviruses: Development of a Novel Vector Based on SpeciesD
Wang et al. Episomal segregation of the adenovirus enhancer sequence by conditional genome rearrangement abrogates late viral gene expression
Shiroki et al. The adenovirus type 12 early-region 1B 58,000-Mr gene product is required for viral DNA synthesis and for initiation of cell transformation
Both Xenogenic adenoviral vectors
Baxi et al. Mutational analysis of early region 4 of bovine adenovirus type 3
Li et al. A recombinant replication-defective human adenovirus type 3: a vaccine candidate
Reddy et al. Optimization of bovine coronavirus hemagglutinin-estrase glycoprotein expression in E3 deleted bovine adenovirus-3
Wu et al. Generation of a replication-deficient recombinant human adenovirus type 35 vector using bacteria-mediated homologous recombination
HK1084974B (en) Packaging cells for recombinant adenovirus
Li et al. Analysis of early region 4 of porcine adenovirus type 3
Csaky Preparation of recombinant adenoviruses
Class et al. Patent application title: COMPLEMENTING CELL LINES Inventors: Ronald Vogels (Linschoten, NL) Menzo Jans Emco Havenga (Alphen A/d Rijn, NL) Majid Mehtall (Plobsheim, FR)
Chamberlain et al. Packaging cell lines for generating replication-defective and gutted adenoviral vectors
CN102002484A (zh) 一种腺病毒-甲病毒杂合病毒的制备及其应用
Cultured Epstein-Barr Virus Hybrid− An Adenovirus

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CI01 Publication of corrected invention patent application

Correction item: Inventor Name

Correct: Zuijdgeest David A. T. M.

False: Zuijdgeest David A. T. M.

Number: 07

Volume: 29

CI03 Correction of invention patent

Correction item: Inventor Name

Correct: Zuijdgeest David A. T. M.

False: Zuijdgeest David A. T. M.

Number: 07

Page: The title page

Volume: 29

ERR Gazette correction

Free format text: CORRECT: INVENTOR NAME; FROM: DAVID A. T. M. . ZUIJDGEEST TO: DAVID A. T. M. ZUIJDGEEST

RECT Rectification
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130213

Termination date: 20211004

CF01 Termination of patent right due to non-payment of annual fee